Outbreaks of filovirus hemorrhagic fever: Time to refocus on the patient

被引：42

作者：

Bausch, Daniel G. ^{[1
]}

Feldmann, Heinz

Geisbert, Thomas W.

Bray, Mike

Sprecher, A. G.

Boumandouki, Paul

Rollin, Pierre E.

Roth, Cathy

机构：

[1] Tulane Sch Publ Hlth & Trop Med, Dept Trop Med, 1430 Tulane Ave, New Orleans, LA 70112 USA

[2] USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA

[3] NIH, Bethesda, MD 20892 USA

[4] Ctr Dis Control & Prevent, Atlanta, GA USA

[5] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada

[6] Med Sans Frontieres, Brussels, Belgium

[7] Minist Hlth Populat, Brazzaville, Rep Congo

[8] WHO, CH-1211 Geneva, Switzerland

来源：

JOURNAL OF INFECTIOUS DISEASES | 2007年 / 196卷

关键词：

D O I：

10.1086/520542

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In the 40 years since the recognition of filoviruses as agents of lethal human disease, there have been no specific advances in antiviral therapies or vaccines and few clinical studies on the efficacy of supportive care. On 20 September 2006, experts from 14 countries representing 68 institutions integrally involved in the response to outbreaks of filovirus hemorrhagic fever gathered at the National Microbiology Laboratory of the Public Health Agency of Canada in Winnipeg to discuss possible remedies for this grim situation, in a unique workshop entitled "Marburg and Ebola Hemorrhagic Fever: Feasibility of Prophylaxis and Therapy." A summary of the opportunities for and challenges to improving treatment of filovirus hemorrhagic fevers is presented here.

引用

页码：S136 / S141

页数：6

共 27 条

[1]

[Anonymous], 2001, UN CHRON

[2]

BAUSCH DG, 2007, PHYS INFORM ED RESOU

[3] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[4]

Boumandouki P, 2005, Bull Soc Pathol Exot, V98, P218

[5]

*CDCP, 1998, WHO INF CONTR VIR HA

[6] Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine [J].

Daddario-DiCaprio, Kathleen M. ;

Geisbert, Thomas W. ;

Geisbert, Joan B. ;

Stroher, Ute ;

Hensley, Lisa E. ;

Grolla, Allen ;

Fritz, Elizabeth A. ;

Feldmann, Friederike ;

Feldmann, Heinz ;

Jones, Steven M. .

JOURNAL OF VIROLOGY, 2006, 80 (19) :9659-9666

[7] Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates:: an efficacy assessment [J].

Daddario-DiCaprio, KM ;

Geisbert, TW ;

Ströher, U ;

Geisbert, JB ;

Grolla, A ;

Fritz, EA ;

Fernando, L ;

Kagan, E ;

Jahrling, PB ;

Hensley, LE ;

Jones, SM ;

Feldmann, H .

LANCET, 2006, 367 (9520) :1399-1404

[8] VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice [J].

Enterlein, S ;

Warfield, KL ;

Swenson, DL ;

Stein, DA ;

Smith, JL ;

Gamble, CS ;

Kroeker, AD ;

Iversen, PL ;

Bavari, S ;

Mühlberger, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :984-993

[9] Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference [J].

Geisbert, Thomas W. ;

Hensley, Lisa E. ;

Kagan, Elliott ;

Yu, Erik Zhaoying ;

Geisbert, Joan B. ;

Daddario-DiCaprio, Kathleen ;

Fritz, Elizabeth A. ;

Jahrling, Peter B. ;

McClintock, Kevin ;

Phelps, Janet R. ;

Lee, Amy C. H. ;

Judge, Adam ;

Jeffs, Lloyd B. ;

MacLachlan, Ian .

JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (12) :1650-1657

[10] Treatment of Ebola virus infection with a recombinant inhibitor of factor Vila/tissue factor: a study in rhesus monkeys [J].

Geisbert, TW ;

Hensley, LE ;

Jahrling, PB ;

Larsen, T ;

Geisbert, JB ;

Paragas, J ;

Young, HA ;

Fredeking, TM ;

Rote, WE ;

Vlasuk, GP .

LANCET, 2003, 362 (9400) :1953-1958

← 1 2 3 →